Resonance Health LtdASX: RHT

MRI Muscle Endpoint - Product Update

· Issued by Resonance Health Ltd via ASX

Filed with ASX · · 6 pages · English

Summary by 6ix AI

Resonance Health Ltd has announced the completion of the design and testing of its MRI muscle volume and quality endpoint, marking a significant milestone in its development strategy for MRI endpoints in clinical trials. This endpoint will allow clinical trial sponsors to measure various muscle quality metrics, including intramuscular fat and muscle volume, from a single MRI session. The company plans to offer this investigational endpoint to customers following the completion of necessary software verification and validation activities. The MRI Muscle Endpoint is specifically designed for use in obesity and metabolic trials, addressing the growing need for comprehensive muscle assessments in these studies.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

ASX Announcement – 11 November 2026 MRI MUSCLE VOLUME & QUALITY ENDPOINT DEVELOPMENT UPDATE A MILESTONE IN MRI ENDPOINTS FOR OBESITY & METABOLIC TRIALS Highlights • Design and testing of Resonance Health’s MRI muscle volume and quality endpoint is complete – an important milestone in its...

Resonance Health Ltd on 6ix

Earlier from Resonance Health

Later from Resonance Health

All Resonance Health news releases